The Efficacy and Safety of Intravenous Iron Sucrose in Hemodialysis Patients.
- Author:
Min Seok CHO
1
;
Youn Kyoung LEE
;
Byoung Seok PARK
;
Taek Kyun JEONG
;
Gyun Ho JEONG
;
Seong Kwon MA
;
Soo Wan KIM
;
Nam Ho KIM
;
Ki Chul CHOI
Author Information
1. Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
- Publication Type:Original Article
- Keywords:
Iron sucrose;
Anemia;
Hemodialysis;
Chronic renal failure(CRF)
- MeSH:
Adult;
Anemia;
Blood Pressure;
Chemistry;
Dialysis;
Drug-Related Side Effects and Adverse Reactions;
Ferritins;
Hematocrit;
Humans;
Insurance;
Iron*;
Jeollanam-do;
Kidney Failure, Chronic;
Renal Dialysis*;
Serum Albumin;
Sucrose*;
Transferrin
- From:Korean Journal of Nephrology
2002;21(5):787-796
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The objective of the present study was to assess the efficacy and safety of iron sucrose by determining the subsequent change in hemoglobin (Hgb), hematocrit (Hct), transferrin saturation (TAST), serum ferritin values and blood pressures in hemodialysis patients receiving Epoetin. METHODS: A total of 19 adult patients who had been receiving hemodialysis three times a week at Chonnam Natinal University Hospital were assigned. Their Hgb level was less than 10 g/dL and their serum ferritin level was less than 100 ng/mL, and/or TSAT was less than 20%. Iron sucrose was administered as 1,000 mg in 10 divided doses diluted in 100 mL normal saline over the last 60 minutes during hemodialysis with a one-time prior test dose of 20 mg on 10 consecutive dialysis sessions. Iron sucrose dosage was adjusted to 25-100 mg/week depending on serum ferritin level, and TSAT in the following 3 months. Epoetin administration was stopped due to insurance regulation when Hgb level was more than 10 g/dL and Hct level was more than 30 %. To evaluate efficacy of iron sucrose, assessment of serum iron parameters and anemia indices was determined just before the first dose (baseline), at 1 month after the first dose (loading) and then, monthly for 3 months (maintenance). To evaluate safety of iron sucrose, we recorded blood pressure 1 hour before and at the time of completion of iron sucrose injection, and also recorded blood pressure during observation sessions before dialysis and at intervals of 2 hours and 4 hours after starting dialysis. We determined routine serum chemistry and hematologic results at 1 month after the first dose and compared results with those obtained at baseline. RESULTS: 1,000 mg iron surcose injection in 10 divided dose (loading) produced a significant rise in Hgb, Hct, serum iron, serum ferritin, TSAT, MCV and MCH at 1 month after first dose (respectively p<0.001, p<0.001, p<0.01, p<0.001, p<0.01, p<0.01, p< 0.01). During the following maintenance period of 3 months, Hgb, Hct, serrum ferritin, and TSAT level remained more elevated than at baseline respectively. In 19 enrolled patients, we experienced no serious adverse drug reactions and no significant changes in intradialytic blood pressure associated with iron sucrose administration. Serum albumin concentrations was higher at 1 month than at base line and however, changes in other serum chemistry and hematologic results were not statistically significant. CONCLUSION: Intravenous iron sucrose administration is an efficient and safe method to supply iron in end-stage renal disease patients receiving Epoetin with iron deficiency, who are undergoing hemodialysis.
